Patents Examined by Satyendra Singh
  • Patent number: 8753689
    Abstract: Demineralized bone particles are obtained by demineralizing whole bone and thereafter subdividing the demineralized bone to provide the demineralized bone particles.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 17, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: John W. Morris, Lawrence A. Shimp, Kenneth C. Petersen, Albert Manrique, David Kaes, Nelson Scarborough, Michael Dowd
  • Patent number: 8753806
    Abstract: An organ protectant solution which is intravenously administerable includes a high concentration of cell impermeant molecules which have a charge and/or molecular weight which permit passage across a capillary endothelium and into an interstitial space in said subject but which are too large and/or charged to cross a cell plasma membrane such that said one or more cell impermeant molecules preferentially load into an extracellular fluid compartment can be used to to allow for improved organ harvesting from DCD and brain death donors for transplantation purposes and also can be used extend the “Golden Hour” for traumatic and hemorrhagic shock patients thereby allowing more time for those patients to reach a point of care facility to receive medical treatment.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: June 17, 2014
    Assignee: Virginia Commonwealth University
    Inventor: Martin Mangino
  • Patent number: 8658391
    Abstract: The present invention provides methods for assessing the activity of topically administered chemodenervating agents. In some embodiments, methods for assessing the activity of topically administered chemodenervating agents involve determining the extent of inhibition of acetylcholine release near the site of administration. In some embodiments, methods for assessing activity of topically administered chemodenervating agents involve observing a reflex motion of a limb of a subject.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: February 25, 2014
    Assignee: Anterios, Inc.
    Inventor: Jonathan Edelson
  • Patent number: 8642285
    Abstract: A method for monitoring consumption or release of a gaseous analyte such as oxygen by a liquid sample under investigation includes providing a cuvette (1) having an elongate narrow tube (12) of a material which is substantially gas impermeable and which is at least partly transparent to measurement excitation radiation and emission radiation along some of the length of the tube. The tube (12) has a cross-sectional area of under 1 mm2. The sample (15) is loaded into the cuvette (1), the sample being in contact with a probe in the tube (12), the probe being sensitive to the gaseous analyte, and the liquid having at least one surface and an associated headspace (16). The cuvette, the sample, and the probe are equilibrated at a target measurement temperature. Excitation radiation is directed at a sampling zone of the tube (12) and which is distal from the headspace (16), while maintaining the cuvette at the measurement temperature.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: February 4, 2014
    Assignee: Luxcel Biosciences Limited
    Inventor: Dmitri Boris Papkovsky
  • Patent number: 8642288
    Abstract: Provided is a method of focusing particles. The method includes: providing a suspension of the particles in a suspending medium; and flowing the suspension along a channel, such that the flowing suspension occupies a certain volume that has at least one cross-sectional dimension smaller than 100 ?m. The suspending medium has such viscoelastic properties, that flowing the suspension in the channel directs at least some of the particles towards a focus region, enclosed in said certain volume.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 4, 2014
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Alexander Leshansky, Avishay Bransky, Korin Natanel
  • Patent number: 8637066
    Abstract: A biocompatible ligament repair implant or scaffold device is provided for use in repairing a variety of ligament tissue injuries. The repair procedures may be conducted with ligament repair implants that contain a biological component that assists in healing or tissue repair. The biocompatible ligament repair implants include a biocompatible scaffold and particles of viable tissue derived from ligament tissue or tendon tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: January 28, 2014
    Assignee: DePuy Mitek, LLC
    Inventors: Francois Binnette, Julia Hwang, Mark Zimmerman, Mora Carolynne Melican
  • Patent number: 8603464
    Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: December 10, 2013
    Assignee: Zoltan Laboratories LLC
    Inventor: Zoltan Kiss
  • Patent number: 8592198
    Abstract: The invention relates to a microorganism growth substrate which comprises a sterile nutrient composition derived from the biomass of a culture of bacteria including methanotrophic bacteria and further containing at least one sterile nutrient. A preferred biomass material is that derived from a microbial culture comprising Methylococcus capsulates (Bath) (strain NCIMB 41526), Ralstonia sp. DB3 (strain NCIMB 41527) and Brevibacillus agri DB5 (strain NCIMB 41525), optionally in combination with Aneurinibacillus sp. DB4 (strain NCIMB 41528).
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: November 26, 2013
    Assignee: Statoil ASA
    Inventors: Einar Moen, Jeanette Moller Jorgensen, Karen Moller Jensen, Arild Johannessen
  • Patent number: 8580558
    Abstract: This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include quantitation of iron derived from plant or animal ferritin.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: November 12, 2013
    Assignee: Slo-Iron, LLC
    Inventor: Elizabeth C. Theil
  • Patent number: 8563251
    Abstract: The invention provides compositions (e.g., kits) and methods for determine the number of bacteria and other microbes in samples having low concentrations of microbes, for use, e.g., in biological warfare defense, microbe detection and agricultural and environmental sciences.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: October 22, 2013
    Assignee: San Diego State University (SDSU) Foundation
    Inventors: Forest Rohwer, Linda Wegley
  • Patent number: 8562975
    Abstract: The present invention relates to a method for stabilizing reduced coenzyme Q10, which is useful as an ingredient in good foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs, etc., and to a composition therefor. The composition comprises reduced coenzyme Q10, a fat and oil (excluding olive oil) and/or a polyol, and doesn't substantially inhibit the stabilization of reduced coenzyme Q10. Additionally, the composition is a reduced coenzyme Q10-containing composition which comprises reduced coenzyme Q10, a polyglycerol fatty acid ester, and a fat and oil and/or a polyol.
    Type: Grant
    Filed: January 20, 2003
    Date of Patent: October 22, 2013
    Assignee: Kaneka Corporation
    Inventors: Yasuyoshi Ueda, Takahiro Ueda, Tadao Ono, Shiro Kitamura, Kenji Fujii, Kazunori Hosoe
  • Patent number: 8545836
    Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. A composition of the invention comprises an oral delivery vehicle comprising an oxalate degrading bacteria, one or more cryopreserving agents and one or more excipients. A composition of the invention is enteric coated and has a suitable shelf-life and acceptable properties to avoid negative impact from gastric fluid when it is orally administered.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: October 1, 2013
    Assignee: Oxthera, Inc.
    Inventors: Poonam Kaul, Harmeet Sidhu
  • Patent number: 8541182
    Abstract: Inflammatory state in a subject is assayed by determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A3AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A3AR agonist.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: September 24, 2013
    Assignee: Can-Fite Biopharma Ltd.
    Inventors: Pnina Fishman, Sara Bar-Yehuda, Lea Madi
  • Patent number: 8535662
    Abstract: This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are pathophysiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: September 17, 2013
    Assignee: Apt Therapeutics, Inc.
    Inventors: Ridong Chen, Soon Seog Jeong
  • Patent number: 8529962
    Abstract: Demineralized bone particles are obtained by demineralizing whole bone and thereafter subdividing the demineralized bone to provide the demineralized bone particles.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: September 10, 2013
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: John W. Morris, Lawrence A. Shimp, Kenneth C. Petersen, Albert Manrique, David Kaes, Nelson Scarborough, Michael Dowd
  • Patent number: 8524225
    Abstract: The present invention relates to a process for the proteolytic hydrolysis of a peptide or a polypeptide, said peptide or polypeptide comprising 4 to 40, preferably 5 to 35, amino acid residues and said peptide or polypeptide is not hydrolysable by subtilisin whereby said peptide or polypeptide is hydrolysed by a proline specific endo protease at a pH of 6.5 or lower, preferably 5.5 or lower and more preferably 5.0 or lower to hydrolyse said peptide or polypeptide.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: September 3, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Luppo Edens, Melissa Harvey, Robertus Antonius Mijndert Van Der Hoeven, Andre Leonardus De Roos
  • Patent number: 8506956
    Abstract: The present invention has its object to provide a method for stabilizing reduced coenzyme Q10, which is usable as foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs and the like. Reduced coenzyme Q10, which is readily oxidized in the air, is stabilized by causing ascorbic acid or a related compound thereof to coexist with a polyglycerol fatty acid ester with a polymerization degree of glycerol being not lower than 3 and/or a condensed ricinoleic acid polyglyceride in a mixture of the reduced coenzyme Q10 and an oil and fat.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: August 13, 2013
    Assignee: Kaneka Corporation
    Inventors: Takahiro Ueda, Shiro Kitamura, Yasuyoshi Ueda
  • Patent number: 8501476
    Abstract: Provided are assays and methods for creating proto-tissues from aggregates of cells. The invention concerns assays and methods useful in tissue engineering and reconstruction techniques, specifically in the formation of macrotissues from microtissues using microtissue pre-culture time as a controlling parameter.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: August 6, 2013
    Assignee: Brown University
    Inventors: Jeffrey R. Morgan, Dylan Dean, Adam Rago
  • Patent number: 8496970
    Abstract: A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: July 30, 2013
    Assignee: DePuy Mitek, LLC
    Inventors: Francois Binette, Joseph J. Hammer, Krish Mukhopadhyay, Joel Rosenblatt
  • Patent number: 8481028
    Abstract: The invention relates to compositions for preparing a beverage, the compositions comprise a microorganism and/or an enzyme capable of hydrolysing chlorogenic acids of a coffee extract to phenolic acids. When a beverage prepared with the compositions of the invention is consumed chlorogenic acids present in coffee extract is hydrolysed to improve antioxidant and/or anti-inflammatory properties compared to a similar conventional beverage.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: July 9, 2013
    Assignee: Nestec S.A.
    Inventors: Rachid Bel-Rhlid, Karin Kraehenbuehl, Christophe Cavin, Thomas Wolfgang Raab, Nicolas Page